Indication
Arrhythmogenic Cardiomyopathy
3 clinical trials
4 products
Clinical trial
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantStatus: Recruiting, Estimated PCD: 2026-02-01
Product
LX2020Product
IC14Clinical trial
Phase 1b Study of IC14 in Arrhythmogenic CardiomyopathyStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
TideglusibProduct
Placebo